Efficacy Of Guishao Huoxue Decoction Combined With Udca Of Treatment For Primary Biliary Cirrhosis(PBC)

The subject by observing the normalized joint Shao Huo Xue Tang ursodeoxycholic acid treatment of primary biliary cirrhosis TCM symptoms and signs integral and serum biochemical indices, changes in the human functional status indicators Huoxue Tang ursodeoxycholic acid treatment on GuishaoPBC effects were observed to explore the pros and cons of Traditional Chinese Medicine combined UDCA and its therapeutic effect, which is the treatment of PBC, to seek new and effective treatment.The cases of clinical research in the Jiangsu Province Hospital of Traditional Chinese Medicine in March2010-March2012inpatients and outpatients of50patients with primary biliary cirrhosis patients were randomly divided into two groups, treatment group (n=27), malethree cases,24cases aged38to74years, the average (56.52±10.41) years of age; control group of23cases,3males and20females, aged33to75years, the average (58.04±11.98) years. Decoction combined UDCA treatment Guishao is set to the treatment group, UDCA treatment alone served as controls. Before treatment, the selected basic signs, no significant difference (>0.05), comparable analysis. Were observed before and after treatment in patients with PBC nine signs and symptoms (anorexia, Shenpi fatigue, itchy skin, flank irritation, abdominal distention, liver face, Pollution lump in the abdomen, jaundice, liver palpable pain) and six and biochemical (serum of ALT, AST, ALP, and GGT, TBIL PT), tongue coating, pulse changes, human functional status score, and B-integral. Respectively, were detected in the treatment of stage3,6months1. Syndrome score and biochemical parameters were statistically analyzed to determine the clinical efficacy.Two sets of symptoms in the treatment of0and3and6months, the points between the two groups TCM symptoms, the treatment group compared to the control group, with significant differences (p<0.1); two groups of AST, ALT, ALP, and GGTTBIL and after treatment,3and6months of treatment compared to0to improve significantly (p <0.01); control group after treatment of AST, ALT,, the ALP, TB than before decreased (p <0.01), more than indicators before and after treatmentwas no significant difference (P>0.05). Between the two groups at O, between the two groups the difference was not statistically significant (p>0.05), indicating comparable between the two groups. Treatment three months before the TB and GGT compared with significantly decreased, the difference was statistically significant (p <0.01); decreased significantly in the treatment of the first6months of AST, ALT, and GGT, ALP, compared with before treatment, with significant difference (p <0.01), TB treatment6months also decreased, the difference was statistically significant (p <0.05), results show that the two groups are effective for liver function improvement in both groups compared with significantly higher statistically significant; white blood cells in the treatment of3months and6months than before, the difference was statistically significant (P <0.01), platelet increase in six months of treatment than before treatment, with significant differences before and after treatment (p <0.05), I index difference not statistically significant. Platelets after treatment than before, the treatment group increased significantly (p <0.01), the parameters had no statistically significant difference before and after treatment (P>0.05); two groups of patients with human functional status scores were statistically treated, in the treatment of0and6months, a significant difference (p <0.05); tongue pulse of patients after treatment, the treatment group than in the control group change significantly, and the treatment group between the two groups also improved significantly, indicating that the difference was statistically significant (P <0.01).; super-integral B, statistical analysis, the treatment group and control group, after treatment, no significant difference was not statistically significant (P>0.05).Through this clinical observation, the treatment group than the control group, there are obvious advantages. Found Huoxue Tang UDCA Guishao can improve the serum biochemical parameters, and the patient’s own immune function, improved significantly in patients with signs and symptoms and prolong survival time and reduce complications. Can improve the human functional status of patients with cirrhosis and the overall efficacy of the treatment of PBC, of great significance. The combination therapy of Chinese and Western medicine, effectively improve the effect of ursodeoxycholic acid treatment, and enhance both synergy and significance in PBC treatment and prognosis.